|
Video: What is a Stock Split?
|
|
Heron Therapeutics is a commercial-stage biotechnology company focused on developing treatments for acute care and oncology patients. Co.'s oncology care product portfolio includes SUSTOL, which is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. Co.'s acute care product portfolio includes: ZYNRELEF, which is indicated in adults for soft tissue or periarticular instillation; and APONVIE (HTX-019), which is indicated for the prevention of postoperative nausea and vomiting in adults. According to our HRTX split history records, Heron Therapeutics has had 0 splits. | |
|
Heron Therapeutics (HRTX) has 0 splits in our HRTX split history database.
Looking at the HRTX split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Heron Therapeutics shares, starting with a $10,000 purchase of HRTX, presented on a split-history-adjusted basis factoring in the complete HRTX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$14.95 |
|
End price/share: |
$2.77 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-81.47% |
|
Average Annual Total Return: |
-15.52% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,852.42 |
|
Years: |
10.00 |
|
|
|
|
|